Literature DB >> 2229304

Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.

E Ghigo1, S Goffi, M Nicolosi, E Arvat, F Valente, E Mazza, M C Ghigo, F Camanni.   

Abstract

At present, the mechanism(s) underlying the reduced spontaneous and stimulated GH secretion in aging is still unclear. To obtain new information on this mechanism(s), the GH responses to both single and combined administration of GH-releasing hormone (GHRH; 1 microgram/kg iv) and arginine (ARG; 30 g infused over 30 min), a well known GH secretagogue probably acting via inhibition of hypothalamic somatostatin release, were studied in seven elderly normal subjects and seven young healthy subjects. Basal GH levels were similar in both groups, while insulin-like growth factor-I levels were lower in elderly subjects (76.7 +/- 9.2 vs. 258.3 +/- 29.2 micrograms/L; P = 0.01). In aged subjects GHRH induced a GH increase (area under the curve, 314.9 +/- 91.9 micrograms/L.h) which was lower (P = 0.01) than that in young subjects (709.1 +/- 114.4 micrograms/L.h). On the other hand, the ARG-induced GH increase in the elderly was not significantly different from that in young subjects (372.8 +/- 81.8 vs. 470.6 +/- 126.5 micrograms/L.h). ARG potentiated GH responsiveness to GHRH in both elderly (1787.1 +/- 226.0 micrograms/L.h; P = 0.0001 vs. GHRH alone) and young subjects (2113.0 +/- 444.3 micrograms/L.h; P = 0.001 vs. GHRH alone). The potentiating effect of ARG on the GHRH-induced GH response was greater in elderly than in young subjects (1013.0 +/- 553.5% vs. 237.9 +/- 79.1%; P = 0.0001); thus, the GH increase induced by combined administration of ARG and GHRH overlapped in two groups. In conclusion, these results show that, differently from the GHRH-induced GH increase, the somatotroph response to combined administration of ARG and GHRH does not vary with age. Our finding suggests that an increased somatostatinergic activity may underlie the reduced GH secretion in normal aging.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2229304     DOI: 10.1210/jcem-71-6-1481

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

1.  Pituitary reserve after repeated administrations of releasing hormones in young and in elderly men: reproducibility on different days.

Authors:  A E Pontiroli; S Ruga; P Maffi; L Scaglia; M G Perfetti; G Pozza
Journal:  J Endocrinol Invest       Date:  1992-09       Impact factor: 4.256

Review 2.  Ageing, growth hormone and physical performance.

Authors:  F Lanfranco; L Gianotti; R Giordano; M Pellegrino; M Maccario; E Arvat
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 3.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 4.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

5.  Plasma GH responses to GHRH, arginine, L-dopa, pyridostigmine, sequential administrations of GHRH and combined administration of PD and GHRH in Turner's syndrome.

Authors:  K Hanew; A Tanaka; A Utsumi
Journal:  J Endocrinol Invest       Date:  1998-02       Impact factor: 4.256

Review 6.  Potential applications of GH secretagogs in the evaluation and treatment of the age-related decline in growth hormone secretion.

Authors:  G R Merriam; D M Buchner; P N Prinz; R S Schwartz; M V Vitiello
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

Review 7.  Growth hormone cotreatment with gonadotropins in ovulation induction.

Authors:  P G Artini; A A de Micheroux; G D'Ambrogio
Journal:  J Endocrinol Invest       Date:  1996-12       Impact factor: 4.256

8.  Evaluation of growth hormone response to GHRH plus arginine test in children with idiopathic short stature: role of peak time.

Authors:  M Castagno; A Monzani; S Zanetta; G Genoni; E Giglione; R Ricotti; G Bona; F Prodam; S Bellone
Journal:  J Endocrinol Invest       Date:  2018-02-08       Impact factor: 4.256

9.  Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age.

Authors:  A Colao; S Spiezia; C Di Somma; R Pivonello; P Marzullo; F Rota; T Musella; R S Auriemma; M C De Martino; G Lombardi
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

10.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.